Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation

Cell Rep. 2023 Jun 27;42(6):112578. doi: 10.1016/j.celrep.2023.112578. Epub 2023 Jun 1.

Abstract

Chondrosarcomas are the most common malignancy of cartilage and are associated with somatic mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 genes. Somatic IDH mutations are also found in its benign precursor lesion, enchondromas, suggesting that IDH mutations are early events in malignant transformation. Human mutant IDH chondrosarcomas and mutant Idh mice that develop enchondromas investigated in our studies display glycogen deposition exclusively in mutant cells from IDH mutant chondrosarcomas and Idh1 mutant murine growth plates. Pharmacologic blockade of glycogen utilization induces changes in tumor cell behavior, downstream energetic pathways, and tumor burden in vitro and in vivo. Mutant IDH1 interacts with hypoxia-inducible factor 1α (HIF1α) to regulate expression of key enzymes in glycogen metabolism. Here, we show a critical role for glycogen in enchondromas and chondrosarcomas, which is likely mediated through an interaction with mutant IDH1 and HIF1α.

Keywords: CP: Cancer; CP: Metabolism; cancer; chondrosarcoma; development; genetic mutation; glycogen; metabolism; mutant IDH.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Neoplasms / metabolism
  • Cartilage / metabolism
  • Chondroma*
  • Chondrosarcoma* / genetics
  • Chondrosarcoma* / metabolism
  • Chondrosarcoma* / pathology
  • Humans
  • Isocitrate Dehydrogenase* / genetics
  • Isocitrate Dehydrogenase* / metabolism
  • Mice
  • Mutation / genetics

Substances

  • Isocitrate Dehydrogenase